MPO and type 1 diabetes mellitus: In contrast, inhibitors that specifically target enzymatic products of neutrophils/NETosis (NE, MPO) or that neutralize NET/histone toxicity have had variable outcomes on T1D incidence (15, 44, 45), with most approaches failing to prevent T1D onset (15, 44).